These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
459 related items for PubMed ID: 26997382
1. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study. Shaheen FA, Kurpad R, Al-Sayyari AA, Souqiyyeh MZ, Aljubori H, El Baz T, Kashif W, Tuganbekova S, Kabulbayev K, Jarraya F, Nafar M. Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382 [Abstract] [Full Text] [Related]
2. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R. J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389 [Abstract] [Full Text] [Related]
3. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ, Shaheen FA. Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [Abstract] [Full Text] [Related]
4. Adaptation and implementation of the "Kidney Disease: Improving Global Outcomes (KDIGO)" guidelines for evaluation and management of mineral and bone disorders in chronic kidney disease for practice in the Middle East countries. Al Rukhaimi M, Al Sahow A, Boobes Y, Goldsmith D, Khabouth J, El Baz T, Mahmoud H, Ganji MR, Shaheen FA, Kidney Disease: Improving Global Outcomes. Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):133-48. PubMed ID: 24434398 [Abstract] [Full Text] [Related]
5. Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Manns BJ, Hodsman A, Zimmerman DL, Mendelssohn DC, Soroka SD, Chan C, Jindal K, Klarenbach S. Am J Kidney Dis; 2010 May; 55(5):800-12. PubMed ID: 20438984 [No Abstract] [Full Text] [Related]
6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V, Torregrosa V. Nefrologia; 2008 May; 28 Suppl 3():67-78. PubMed ID: 19018742 [Abstract] [Full Text] [Related]
9. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Wesseling-Perry K, Salusky IB. Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010 [Abstract] [Full Text] [Related]
13. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe]. Jean G, Daugas É, Roth H, Drueke T, Bouchet JL, Hannedouche T, London G, Fouque D. Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391 [Abstract] [Full Text] [Related]
14. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E. Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962 [Abstract] [Full Text] [Related]